These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Botulinum toxin A and B: a comparative dosing study for spasmodic dysphonia. Blitzer A Otolaryngol Head Neck Surg; 2005 Dec; 133(6):836-8. PubMed ID: 16360499 [TBL] [Abstract][Full Text] [Related]
5. [Botulinum toxin type B in the management of dystonia non-responsive to botulinum toxin type A]. Cardoso F Arq Neuropsiquiatr; 2003 Sep; 61(3A):607-10. PubMed ID: 14513166 [TBL] [Abstract][Full Text] [Related]
6. Clinical application of botulinum toxin in otolaryngology, head and neck practice (brief review). Yin S; Stucker FJ; Nathan CO J La State Med Soc; 2001 Feb; 153(2):92-7. PubMed ID: 11261363 [TBL] [Abstract][Full Text] [Related]
7. A comparison of the VHI, VHI-10, and V-RQOL for measuring the effect of botox therapy in adductor spasmodic dysphonia. Morzaria S; Damrose EJ J Voice; 2012 May; 26(3):378-80. PubMed ID: 20951552 [TBL] [Abstract][Full Text] [Related]
8. Botulinum toxins types A and B for brow furrows: preliminary experiences with type B toxin dosing. Lowe NJ; Yamauchi PS; Lask GP; Patnaik R; Moore D J Cosmet Laser Ther; 2002 Mar; 4(1):15-8. PubMed ID: 12079632 [TBL] [Abstract][Full Text] [Related]
9. [Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis]. Wissel J; Entner T Wien Klin Wochenschr; 2001; 113 Suppl 4():20-4. PubMed ID: 15506048 [TBL] [Abstract][Full Text] [Related]
13. [Laryngeal dystonia: novel forms of therapeutic administration of botulinum toxin by direct routes]. Lopez Del Val LJ; Sebastian-Cortes JM; Bellosta-Diago E; Santos-Lasaosa S; Vinueza-Buitron PR; Lois-Ortega Y; Valles-Varea H; Lopez-Garcia E Rev Neurol; 2018 Jun; 66(11):368-372. PubMed ID: 29790569 [TBL] [Abstract][Full Text] [Related]
14. A prospective crossover trial of botulinum toxin chemodenervation versus injection augmentation for essential voice tremor. Estes C; Sadoughi B; Coleman R; Sarva H; Mauer E; Sulica L Laryngoscope; 2018 Feb; 128(2):437-446. PubMed ID: 28988441 [TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of botulinum toxin therapy in otorhinolaryngology: experience from 1,000 treatments. Helmstaedter V; Wittekindt C; Huttenbrink KB; Guntinas-Lichius O Laryngoscope; 2008 May; 118(5):790-6. PubMed ID: 18300708 [TBL] [Abstract][Full Text] [Related]
16. Reconstituted botulinum toxin type A does not lose potency in humans if it is refrozen or refrigerated for 2 weeks before use. Sloop RR; Cole BA; Escutin RO Neurology; 1997 Jan; 48(1):249-53. PubMed ID: 9008526 [TBL] [Abstract][Full Text] [Related]
17. Questioning the need to use Botox within 4 hours of reconstitution: a study of fresh vs 2-week-old Botox. Yang GC; Chiu RJ; Gillman GS Arch Facial Plast Surg; 2008; 10(4):273-9. PubMed ID: 18645097 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of botulinum toxin type A in treatment of different forms of focal dystonias in the Serbian population: experience of the Botulinum Toxin Outpatients Department. Tomić A; Vujović B; Svetel M; Misković ND; Petrović I; Pekmezović T; Kostić VS Vojnosanit Pregl; 2015 Dec; 72(12):1069-73. PubMed ID: 26898029 [TBL] [Abstract][Full Text] [Related]
19. [Diagnostic and therapeutic difficulties in laryngeal dystonia]. Niebudek-Bogusz E; Modzelewska-Radwan B; Pietruszewska W; Zielińska M; Gryczyński M Otolaryngol Pol; 2003; 57(5):739-45. PubMed ID: 14994622 [TBL] [Abstract][Full Text] [Related]
20. Relationship of botulinum dosage to duration of side effects and normal voice in adductor spasmodic dysphonia. Chang CY; Chabot P; Thomas JP Otolaryngol Head Neck Surg; 2007 Jun; 136(6):894-9. PubMed ID: 17547976 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]